Impedimed Limited · ASX:IPD
Impedimed — Shareholder Meeting (November 2025)
22 slides from Impedimed's shareholder meeting presentation, Nov 18, 2025
Slide 1: 2025 Annual General Meeting – CEO's Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 18 November 2025 For personal use only Companies Announcements Office Australian Securi<es Exchange 2025 Annual General Mee.ng – CEO’s Presenta.on ImpediMed Limited (ImpediMed) (ASX:I
Slide 2: Forging New Standards of Care
For personal use only Forging New Standards of Care Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: 2025 AGM CEO Presentation Agenda
2025 AGM CEO Presentation For personal use only Video Overview SOZO® Market Opportunity AGENDA BCRL Update Cardiometabolic Business Financials Strategy for the Next Year
Slide 5: SOZO Digital Health Platform with Multiple FDA Cleared Applications
SOZO® Digital Health Platform with Multiple FDA Cleared Applications One device, multiple FDA cleared applications For personal use only Lymphoedema A single SOZO measurement provides: ✓ FDA clearance • L-Dex® lymphoedema analysis ✓ CE Mark • HF-Dex® heart failure analysis ✓ TGA clearance • Body Com
Slide 6: Expanding SOZO to Growing US Patient Populations
Expanding SOZO® to Growing US Patient Populations Cancer Survivorship Cardiometabolic Health Outcomes For personal use only Weight Lymphoedema Management $600m TAM Heart Failure Unmanaged $650m TAM 4m Breast Cancer Weight 13m US Obesity Sarcopenia $1.1b TAM Loss 6m Patients Survivors1 patients on GL
Slide 7: SOZO Workflow fits into current clinical workflow
SOZO Workflow fits into current clinical workflow to extend from cancer survivorship into cardiometabolic health For personal use only Patient Patient MA reviews SOZO data Clinician Encounter visits their enters the clinical data sent digitally reviews and billed as per local clinic exam room and SO
Slide 8: Cancer Survivorship | Prevention of Breast Cancer Related Lymphoedema
Cancer Survivorship | Prevention of Breast Cancer Related Lymphoedema $600m For personal use only Positive Global Clinical Trial BCRL TAM World-leading Hospitals 1200 patient trial: Statistically Significant Deployed in 18 of Top 25 US Hospitals 2 Lower Progression to Chronic Lymphoedema1 FDA cleare
Slide 9: Cardiometabolic health | Improving Outcomes for Patients Living with Heart Failure
Cardiometabolic health | Improving Outcomes and Quality of Life for Patients living with Heart Failure For personal use only Improving Outcomes and QOL for Patients Living with Heart Failure with financially sustainable solution for Providers The Heart Failure Opportunity US controlled market releas
Slide 10: SOZO Pro For Cardiology Patients
SOZO® Pro For Cardiology Patients For personal use only Comprehensive Body Composition Tracking • SOZO tracks fat, fat-free mass, and skeletal muscle to support personalized rehabilitation and weight management. Fluid Status Monitoring to Guide Treatment • HF-Dex offers a sensitive index of fluid
Slide 11: SOZO Pro for Cardiology
SOZO® Pro for Cardiology For personal use only Proprietary, do not reproduce, Proprietary, distribute, do not or excerpt reproduce, without distribute, writtenwithout or excerpt permission from written ImpediMed. permission from©2023 ImpediMed ImpediMed. ©2023Limited. ImpediMed Limited. 10
Slide 12: Raising the Bar in an Accelerating Weight Management Market
Raising the Bar in an Accelerating Weight Management Market Raising the Bar with BIS: Precision Body Composition with One Scan For personal use only ✓ Sales in progress ✓ Large and Growing Market ✓ Updating messaging and imaging “ Global MedSpa market expected to grow from US $18Billion to $US72 Bil
Slide 13: SOZO Pro for Medically Managed Weight Change
SOZO® Pro for Medically Managed Weight Change For personal use only Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 12
Slide 14: Core Business Revenue and ARR improving
Core Business Revenue and ARR improving For personal use only FY25 Full-Year Results Total revenue SOZO Core SOZO Core Number of patient $12.7 Business1 revenue Business ARR tests conducted million $12.1 million $14.0 million 287,000 23% vs FY24 25% vs FY24 27% vs FY24 15% vs FY24 # SOZO units SOZO
Slide 15: SOZO Core Business Revenue and ARR continues to grow
SOZO Core Business Revenue and ARR continues to grow SOZO Core Business ARR1 For personal use only SOZO Core Business Revenue 24% 3-year CAGR2 A$ millions FY25 SOZO Core Business revenue up ARR up 27% vs. FY24 ($11.0m) 25% vs. FY24 1. Annual Recurring Revenue (ARR) represents the amount of revenue r
Slide 16: Momentum Continues | Forward sales indicators improve
Momentum Continues | Forward sales indicators improve and TCV momentum returns For personal use only U.S. SOZO Units Sales Pipeline1 SOZO Core Business Quarterly TCV Sales Pipeline up 60% Q4 FY25 Pipeline up 60% vs. Q4 FY24 Record quarterly increase in TCV 2 2. Total Contracted Value (TCV) relates t
Slide 17: Patient testing up 15% vs. FY24 and 21% 3-year CAGR
Patient testing up 15% vs. FY24 and 21% 3-year CAGR SOZO Patient Test’s (000s) For personal use only 15% growth vs. FY24 21% 3-year CAGR 21% 3-year An important driver of CAGR1 renewals 1.Compound Annual Growth Rate (based on annual totals). Proprietary, do not reproduce, distribute, or excerpt with
Slide 18: Focus for the Next Year
Focus for the Next Year Drive long term sustainable growth in the business For personal use only 12-Month Priorities Next 12 months: Execute towards profitability July 2026 GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Progress to break Cardiometabolic Rest of World execution ex
Slide 19: AI to drive operational efficiencies and improve customer experience
AI to drive operational efficiencies and improve customer experience For personal use only Software Development Customer Experience Sales Optimization • Unit Test Coverage • CoPilot Knowledge Base • Lead Generation We are adopting Claude Code to generate Company-wide access to CoPilot, trained on Us
Slide 20: The ImpediMed Value Proposition
The ImpediMed Value Proposition For personal use only • Only FDA-cleared BIS technology • Large market supporting cancer survivorship. • Clinically validated and included in major cancer- • Established global footprint, installed in leading care guidelines. hospitals and cancer centers. Advanced Lar
Slide 21: Thank You
For personal use only Thank You 20
Slide 22: Questions
For personal use only Question Procedures Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 21 ©2023 ImpediMed Limited.